

Aaron Mansfield

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6933252/aaron-mansfield-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166 papers	6,517 citations	37 h-index	78 g-index
192 ext. papers	9,263 ext. citations	7 avg, IF	5.81 L-index

#	Paper	IF	Citations
166	New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101567	2.2	2
165	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.. <i>Annals of Oncology</i> , 2022 ,	10.3	10
164	Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.. <i>Frontiers in Oncology</i> , 2022 , 12, 823667	5.3	0
163	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.. <i>Npj Precision Oncology</i> , 2022 , 6, 13	9.8	1
162	The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100315	1.4	0
161	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.. <i>Lung Cancer</i> , 2022 , 167, 8-16	5.9	1
160	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
159	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	3
158	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. <i>Npj Precision Oncology</i> , 2021 , 5, 22	9.8	2
157	First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. <i>Investigational New Drugs</i> , 2021 , 39, 1348-1356	4.3	3
156	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3630-3640	12.9	2
155	Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2021 , 158, 246-252	5.3	0
154	SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 853-865	1.9	1
153	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2021 , 22, 959-969	21.7	48
152	BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 379-388	6.1	7
151	Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 215-219	7.4	4
150	Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. <i>Clinical Lung Cancer</i> , 2021 , 22, e470-e480	4.9	5

149	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 375-386	4.0	209
148	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 467-467	2.2	7
147	Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2651-2656	7.4	0
146	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021 , 39, 619-630	2.2	68
145	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2021 , 1	4.3	8
144	Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers. <i>Hepatology</i> , 2021 ,	11.2	2
143	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021 , 5, 74	9.8	4
142	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100205	1.4	6
141	NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy.. <i>Cancer Immunology Research</i> , 2021 ,	12.5	2
140	Maintaining Equipoise With Maintenance Therapy in Mesothelioma. <i>Clinical Lung Cancer</i> , 2020 , 21, 482-484	4.4	1
139	Optimizing clinical cytology touch preparations for next generation sequencing. <i>Genomics</i> , 2020 , 112, 5313-5323	4.3	1
138	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncolimmunology</i> , 2020 , 9, 1744980	7.2	40
137	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020 , 25, 810-817	5.7	7
136	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2407-2417	2.2	44
135	Osimertinib-Induced Cardiomyopathy. <i>JACC: Case Reports</i> , 2020 , 2, 641-645	1.2	2
134	Correlation of novel ALK with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020 , 77, 601-610	7.3	3
133	Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 143, 86-92	5.9	7
132	Chromosomal rearrangements and their neoantigenic potential in mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, S92-S99	4.4	9

131	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020 , 580, 245-251	50.4	147
130	Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1027-1036	8.9	22
129	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , 2020 , 3, e200202	10.4	12
128	Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. <i>Lung Cancer</i> , 2020 , 141, 82-88	5.9	13
127	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. <i>Annals of Oncology</i> , 2020 , 31, 310-317	10.3	54
126	Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. <i>Frontiers in Oncology</i> , 2020 , 10, 392	5.3	
125	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncolimmunology</i> , 2020 , 9, 1744947	7.2	15
124	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020 , 8, e17353	3.6	4
123	A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 421-427.e2	4.9	10
122	Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 141, 199-208	7.5	6
121	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles 2020 , 8,		12
120	Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e115-e129	4.9	9
119	Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. <i>Human Pathology</i> , 2019 , 94, 78-85	3.7	4
118	Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1286-1295	8.9	32
117	Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019 , 14, e0216485	3.7	20
116	Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine. <i>Abdominal Radiology</i> , 2019 , 44, 2067-2073	3	10
115	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1704-1717	8.9	6
114	Current Diagnosis and Management of Small-Cell Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1599-1622	6.2	89

113	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 402-429	220.7	162
112	Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1567-1582	8.9	28
111	Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2019 , 135, 73-79	5.9	12
110	An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-15	5.2	42
109	Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019 , 25, 5438-5440	12.9	7
108	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1718-1731	8.9	9
107	Understanding Clinical Trials in Malignant Mesothelioma 2019 , 187-202		
106	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019 , 24, e1148-e1155	5.7	45
105	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019 , 24, 96-102	5.7	11
104	Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences. <i>Histopathology</i> , 2019 , 74, 364-367	7.3	5
103	Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion. <i>Clinical Lung Cancer</i> , 2019 , 20, e142-e147	4.9	10
102	Prospective Immunophenotyping of CD8 T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 229-240	4	11
101	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 276-287	8.9	61
100	Predicting Treatment Response Based on RNA Expression in Large Datasets. <i>Clinical Cancer Research</i> , 2019 , 25, 1443-1445	12.9	0
99	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 684-692	4.3	14
98	Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , 2018 , 8, 2171	4.9	50
97	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018 , 359, 926-930	33.3	1204
96	Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 1214-1222	2	19

95 Significance of Immune Checkpoints in Lung Cancer **2018**, 59-77

94	Progress in the Management of Malignant Pleural Mesothelioma in 2017. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 606-623	8.9	45
93	DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKK-dependent cell migration. <i>Communications Biology</i> , 2018 , 1, 43	6.7	14
92	Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1349-1362	8.9	20
91	CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <i>JCI Insight</i> , 2018 , 3,	9.9	62
90	Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. <i>Journal of Oncology Practice</i> , 2018 , 14, e1-e10	3.1	112
89	Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 873-880	7.1	3
88	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. <i>Heliyon</i> , 2018 , 4, e01039	3.6	23
87	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2220-2229	59.2	1236
86	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1655-1667	8.9	50
85	9. Detection of fusion genes from complex rearrangements reported by genome-wide mate-pair sequencing (MPseq). <i>Cancer Genetics</i> , 2018 , 224-225, 53-54	2.3	
84	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1026-1033	6.4	4
83	Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 3277-3284	12.9	59
82	Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. <i>Thrombosis Research</i> , 2017 , 154, 28-34	8.2	29
81	Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years experience at Patan Hospital, Nepal. <i>British Journal of Haematology</i> , 2017 , 177, 991-999	4.5	1
80	OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S296	8.9	6
79	A proof-of-concept trial of protein kinase C δ inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017 , 25, 833-838	3.9	6
78	Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017 , 2, 12-18	3.3	1

77	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 591-592	15.4	2
76	Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	2
75	Predictors of active cancer thromboembolic outcomes: role of body composition. <i>International Angiology</i> , 2017 , 36, 88-89	2.2	1
74	Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer. <i>Oncology Nursing Forum</i> , 2017 , 44, E194-E202	1.7	10
73	Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011. <i>Cancer Medicine</i> , 2017 , 6, 2203-2212	4.8	65
72	Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. <i>Medical Oncology</i> , 2017 , 34, 140	3.7	1
71	FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. <i>Practical Radiation Oncology</i> , 2017 , 7, e531-e541	2.8	6
70	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Oncolmmunology</i> , 2017 , 6, e1356146	7.2	23
69	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017 , 8, 27145-27154	3.3	40
68	Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11534-11534	2.2	12
67	Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8581-TPS8581	2.2	12
66	ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8582-TPS8582	2.2	1
65	EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. <i>Oncotarget</i> , 2017 , 8, 27155-27165	3.3	8
64	Management of Multifocal Lung Cancer: Results of a Survey. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1398-1402	8.1	13
63	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 1953-8	10.3	195
62	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 T cells. <i>Scientific Reports</i> , 2016 , 6, 36722	4.9	26
61	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <i>BioDrugs</i> , 2016 , 30, 397-405	7.9	31
60	Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. <i>Annals of Oncology</i> , 2016 , 27, 2111-2117	10.3	39

59	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2177-82	12.9	92
58	Rapidly Appearing Sclerotic Vertebral Lesions in a Patient With an Infiltrative Mediastinal Mass. <i>JAMA Oncology</i> , 2016 , 2, 267-8	13.4	
57	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016 , 7, 70223-70231	3.3	27
56	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , 2016 , 1,	9.9	52
55	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1773-8	15.4	79
54	Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 220-2	6.1	17
53	The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <i>Clinical Cancer Research</i> , 2016 , 22, 5472-5479	12.9	16
52	S768I Mutation in EGFR in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1798-801	8.9	41
51	c-Met expression and MET amplification in malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2016 , 23, 1-7	2.2	9
50	Radiotherapy for extensive stage small-cell lung cancer. <i>Lancet, The</i> , 2015 , 385, 1291	4.0	2
49	The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. <i>Melanoma Research</i> , 2015 , 25, 59-63	3.3	33
48	Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. <i>Oncolimmunology</i> , 2015 , 4, e1026504	7.2	20
47	Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1416-7	4.7	5
46	Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015 , 136, 1120-5	8.2	13
45	Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. <i>Thrombosis Research</i> , 2015 , 136, 1169-73	8.2	2
44	Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1213-20	8.9	78
43	Development and external validation of a prognostic nomogram for metastatic uveal melanoma. <i>PLoS ONE</i> , 2015 , 10, e0120181	3.7	24
42	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015 , 3, 610-9	12.5	251

4 ¹	DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. <i>Cancer Genetics</i> , 2015 , 208, 253-60	2.3	12
4 ⁰	Primary venous thromboembolism prophylaxis in patients with solid tumors. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 258-9	5.1	
39	Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. <i>Lung Cancer</i> , 2014 , 86, 133-6	5.9	35
38	Effect of β -adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 1164-5	6.4	5
37	Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 38, 241-9	5.1	22
36	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 539-49	4.4	52
35	A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound. <i>Annals of Surgical Oncology</i> , 2014 , 21, 2229-36	3.1	14
34	Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. <i>Journal of Oncology Practice</i> , 2014 , 10, e1-4	3.1	14
33	Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. <i>Journal of Human Genetics</i> , 2014 , 59, 124-8	4.3	23
32	Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. <i>Lung Cancer</i> , 2014 , 86, 358-62	5.9	33
3 ¹	Pregnancy-associated plasma protein-A expression in human breast cancer. <i>Growth Hormone and IGF Research</i> , 2014 , 24, 264-7	2	26
3 ⁰	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1036-1040	8.9	177
29	A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2636-TPS2636	2.2	2
28	Reflections on immune checkpoint inhibition in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014 , 3, 411-3	4.4	9
27	A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3049-3049	2.2	
26	The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20011-e20011	2.2	
25	Association of early venous thromboembolic events with worse prognosis in patients with lung cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20623-e20623	2.2	
24	The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. <i>Current Oncology Reports</i> , 2013 , 15, 207-16	6.3	47

23	Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. <i>Lung Cancer</i> , 2013 , 82, 63-8	5.9	11
22	Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. <i>American Journal of Clinical Pathology</i> , 2013 , 139, 144-50	1.9	29
21	Inhibition of angiogenesis for the treatment of metastatic melanoma. <i>Current Oncology Reports</i> , 2013 , 15, 492-9	6.3	4
20	Phase I dose escalation study of the PKC α inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2013 , 24, 1079-83	2.4	37
19	The immunomodulatory effects of bevacizumab on systemic immunity in patients with α metastatic melanoma. <i>OncolImmunology</i> , 2013 , 2, e24436	7.2	32
18	Asphyxiation with a fentanyl patch. <i>Case Reports in Oncology</i> , 2013 , 6, 242-4	1	4
17	Predictors Of Cancer Associated Thrombosis. <i>Blood</i> , 2013 , 122, 3616-3616	2.2	1
16	Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. <i>Clinical and Experimental Immunology</i> , 2012 , 170, 186-93	6.2	50
15	The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 461, 639-46	5.1	11
14	68-year-old man with neutropenic fever and upper extremity hematoma. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 1226-9	6.4	1
13	Regional lymphatic immunity in melanoma. <i>Melanoma Research</i> , 2012 , 22, 9-18	3.3	15
12	An organ system based approach to prognosis in advanced melanoma. <i>Frontiers in Bioscience - Elite</i> , 2012 , 4, 2723-33	1.6	6
11	Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. <i>Modern Pathology</i> , 2011 , 24, 487-94	9.8	39
10	Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 459, 391-8	5.1	30
9	Resectable pancreatic small cell carcinoma. <i>Rare Tumors</i> , 2011 , 3, e5	1.1	18
8	No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. <i>Blood</i> , 2011 , 118, 4259-4259	2.2	0
7	Angiomatoid fibrous histiocytoma in a 25-year-old male. <i>Rare Tumors</i> , 2010 , 2, e20	1.1	14
6	Hydroxycarbamide-induced dermatopathy. <i>American Journal of Hematology</i> , 2010 , 85, 75-6	7.1	1

5	Mayo Clinic experience with very rare exocrine pancreatic neoplasms. <i>Pancreas</i> , 2010 , 39, 972-5	2.6	16
4	Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. <i>BMC Hematology</i> , 2010 , 10, 8	2.5	2
3	Novel therapeutics for the treatment of metastatic melanoma. <i>Future Oncology</i> , 2009 , 5, 543-57	3.6	15
2	Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. <i>BMC Cancer</i> , 2009 , 9, 231	4.8	80
1	71-Year-Old Man With Chronic Kidney Failure and Sudden Change of Mental Status. <i>Mayo Clinic Proceedings</i> , 2009 , 84, e5-e8	6.4	1